Editas Medicine, Inc. Stock News

Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J.

Editas Medicine, Inc. (NASDAQ:EDIT ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good morning, everyone. My name is Gena Wang, I'm [Indiscernible] at Biotech An...

Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore ...

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-end On track to establish one additional target cell type/tissue by year-end Strong cash position with operational runway into the second quarte...

Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Alexander Kelly - TD Cowen Alexander Kelly Hi everyone. I'm Alex Kelly.

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial resul...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vi...

Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burkly - Executive Vice President and Chief Scientific Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Brian Cheng Good m...